TCGA-E2-A15M-01A-11R-A12D-07
— · A
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- A
- subtype
- A
- overall_survival_months
- 11
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.510
- INTERFERON_GAMMA_RESPONSE+0.500
- INTERFERON_ALPHA_RESPONSE+0.470
- IL6_JAK_STAT3_SIGNALING+0.440
- PROTEIN_SECRETION+0.440
- INFLAMMATORY_RESPONSE+0.430
- COMPLEMENT+0.410
- KRAS_SIGNALING_UP+0.410
- UV_RESPONSE_DN+0.390
- IL2_STAT5_SIGNALING+0.320
Top 10 suppressed
- MYC_TARGETS_V2-0.460
- OXIDATIVE_PHOSPHORYLATION-0.270
- DNA_REPAIR-0.250
- ESTROGEN_RESPONSE_EARLY-0.250
- CHOLESTEROL_HOMEOSTASIS-0.220
- ESTROGEN_RESPONSE_LATE-0.220
- KRAS_SIGNALING_DN-0.210
- GLYCOLYSIS-0.180
- P53_PATHWAY-0.160
- MYOGENESIS-0.110
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-EW-A1IY-01A-11R-A13Q-07 | — | B | 0.864 |
| 2 | TCGA-BH-A1F0-01A-11R-A137-07 | — | D | 0.862 |
| 3 | TCGA-GV-A3QG-01A-11R-A220-07 | — | — | 0.859 |
| 4 | TCGA-AR-A24S-01A-11R-A169-07 | — | A | 0.841 |
| 5 | TCGA-BH-A1FE-01A-11R-A13Q-07 | — | A | 0.841 |
| 6 | SRR5088852 | — | — | 0.841 |
| 7 | TCGA-69-7761-01A-11R-2170-07 | — | cohortA1 | 0.829 |
| 8 | TCGA-DK-A2I4-01A-11R-A21D-07 | — | — | 0.826 |
| 9 | TCGA-98-7454-01A-11R-2045-07 | — | cohortMD2 | 0.825 |
| 10 | TCGA-CV-7090-01A-11R-2016-07 | — | — | 0.822 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 28 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.510 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.500 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.470 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.440 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.440 | Remibrutinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.430 | Idelalisib | — uncovered |
| COMPLEMENT | 0.410 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.410 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.390 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.320 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.310 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.310 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.300 | Remibrutinib | — uncovered |
| G2M_CHECKPOINT | 0.290 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.290 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.250 | Cobimetinib | — uncovered |
| ANDROGEN_RESPONSE | 0.240 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.220 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.220 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.210 | Inavolisib | — uncovered |